Izabela Fokt

USPTO Granted Patents = 23 (Patent Applications = 6)

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 8 (Patent Applications = 10)

Average Co-Inventor Count = 5.6

ph-index = 5

Forward Citations = 137(Granted Patents)

Location History:

The Woodlands, TX (US) (1999 - 2004)
Spring, TX (US) (2008 - 2011)
Houston, TX (US) (2010 - 2024)

Company Filing History:

20 out of 5,469

The University of Texas System

patents

1 out of 155

The University of Mississippi

patents

2 out of 832,880

Other

patents

Years Active: 1999-2024

Loading Chart...

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11925654 - Esters of 2-deoxy-monosaccharides with anti proliferative activity (2024-03-12),

2. 11026960 - Esters of 2-deoxy-monosaccharides with anti proliferative activity (2021-06-08),

3. 10703721 - Caffeic acid derivatives and uses thereof (2020-07-07),

4. 10358439 - DNA binding agents with a minor groove binding tail (2019-07-23),

5. 10201554 - Esters of 2-deoxy-monosacharides with anti proliferative activity (2019-02-12),

6. 9149489 - Inhibitors of glycolysis useful in the treatment of brain tumors (2015-10-06),

7. 9096499 - Compounds for treatment of cell proliferative diseases (2015-08-04),

8. 9000179 - Inhibitors of proliferation and activation of signal transducer and activator of transcription (STATs) (2015-04-07),

9. 8927506 - Acetates of 2-deoxy monosaccharides with anticancer activity (2015-01-06),

10. 8779151 - Orally bioavailable caffeic acid related anticancer drugs (2014-07-15),

11. 8648102 - Compounds for treatment of cell proliferative diseases (2014-02-11),

12. 8637675 - Inhibitors of proliferation and activation of signal transducer and activators of transcription (STATS) (2014-01-28),

13. 8299033 - Iodo-hexose compounds useful to treat cancer (2012-10-30),

14. 8252740 - Thermally-targeted delivery of medicaments including doxorubicin (2012-08-28),

15. 8143412 - Inhibitors of proliferation and activation of signal transducer and activator of transcription (STATs) (2012-03-27),

Title: Innovator Spotlight: Izabela Fokt from Houston, TX

Introduction

Izabela Fokt is a distinguished inventor based in Houston, Texas, known for her remarkable contributions to the field of chemistry and medicinal innovations. With a total of 23 patents to her name, she has made significant strides in developing methods that target and inhibit glycolysis, paving the way for potential cancer treatments and therapies for various diseases.

Latest Patents

Fokt's latest groundbreaking patents include "Esters of 2-deoxy-monosaccharides with anti-proliferative activity - Compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases." This innovative work not only emphasizes her expertise but also showcases her dedication to tackling pressing health challenges through her inventions.

Career Highlights

Her career has been marked by impactful roles within the University of Texas System, where she leveraged her research skills and innovative mindset to contribute to advancements in her field. Izabela’s work is characterized by a blend of scientific research and practical application, illustrating her commitment to translating scientific discoveries into viable solutions.

Collaborations

Throughout her career, Fokt has collaborated with esteemed professionals such as Waldemar Priebe and Timothy Madden, further enriching her research and amplifying the impact of her inventions. These collaborations reflect her ability to work effectively within teams and contribute to collective scientific endeavors.

Conclusion

Izabela Fokt's journey as an inventor highlights the importance of innovation in health sciences. With her patents addressing critical medical challenges, she continues to exemplify the transformative power of research and invention in making a meaningful difference in society. Her work not only contributes to scientific knowledge but also offers hope for improved therapeutic options in the medical field.

This text is generated by artificial intelligence and may not be accurate.